Endo, Impax Look To Nix Opana Pay-For-Delay Suits
Endo Pharmaceuticals Inc. and Impax Laboratories sought Friday to dismiss proposed class actions claiming Endo paid more that $112 million to delay a generic version of painkiller Opana ER, saying the...To view the full article, register now.
Already a subscriber? Click here to view full article